MAPK
Las MAPK son una familia de quinasas de proteínas involucradas en una variedad de procesos celulares, incluyendo crecimiento, proliferación, diferenciación y respuestas al estrés. La vía de señalización MAPK consta de varios niveles, incluidos ERK, JNK y p38 MAPK, cada uno con roles distintos en la función celular. La desregulación de la señalización MAPK está vinculada al cáncer, las enfermedades inflamatorias y los trastornos metabólicos. En CymitQuimica, ofrecemos una amplia gama de inhibidores y activadores de MAPK para apoyar su investigación en biología celular, transducción de señales y mecanismos de enfermedades.
Se han encontrado 881 productos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Setidegrasib
CAS:<p>KRAS G12D inhibitor 17, a quinazoline-linked prolinamide, degrades mutant KRAS protein; a PROTAC.</p>Fórmula:C60H65FN12O7SForma y color:SolidPeso molecular:1117.3Natsudaidain
<p>Natsudaidain is a useful organic compound for research related to life sciences and the catalog number is T124974.</p>Fórmula:C21H22O9Forma y color:SolidPeso molecular:418.398NUCC-0200808
<p>NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.</p>Forma y color:Odour SolidMAPK Inhibitor Library
<p>A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;</p>Forma y color:Odour SolidTagarafdeg
CAS:<p>Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.</p>Fórmula:C45H49F2N11O9SPureza:＞99.99%Forma y color:SolidPeso molecular:958U0124
CAS:<p>Inactive analog of U0126(MEK-1/2 inhibitor), used as a negative control</p>Fórmula:C8H10N4S2Pureza:98%Forma y color:SolidPeso molecular:226.32MEK/RAF-IN-1
<p>MEK/RAF-IN-1 (Compound 16b) serves as an inhibitor targeting both MEK and RAF, demonstrating potent efficacy with IC 50 values reported at 28 nM for MEK1, and 3 nM for both BRAF and BRAFV600E. This compound exhibits significant antitumor capabilities, effectively curbing cell proliferation in vitro in MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Furthermore, MEK/RAF-IN-1 significantly restricts tumor growth in xenograft mouse models employed in the study of colorectal cancer.</p>Fórmula:C28H29F3N6O5SForma y color:SolidPeso molecular:618.63KRas G12R inhibitor 1
<p>KRas G12R inhibitor 1 targets mutant cysteines in K-Ras, binds irreversibly, and is used in cancer research.</p>Fórmula:C39H38ClF7N6O9Forma y color:SolidPeso molecular:903.2JIP-1(153-163)
CAS:<p>Peptide based on JIP-1(153-163) inhibits JNK with micromolar affinity; barely affects p38, ERK.</p>Fórmula:C61H104N20O14Pureza:98%Forma y color:SolidPeso molecular:1341.6S6 Kinase Substrate Peptide 32
S6 Kinase Substrate Peptide 32 is a peptide that measures the activity of kinases that phosphorylate ribosomal protein S6. It can also be used as a substrate.Fórmula:C149H270N56O49Pureza:98%Forma y color:SolidPeso molecular:3630.1Mitogen-activated protein kinase 1
CAS:<p>Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.</p>Pureza:98%Forma y color:SolidJNK-IN-18
JNK-IN-18 (compound 23b) is a potent inhibitor of JNK1, boasting an IC50 of 2 nM. It demonstrates superior efficacy when compared to its IC50 values of 125 nM for JNK2 and 98 nM for BRAF(V600E).Forma y color:Odour SolidR18
CAS:<p>14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.</p>Fórmula:C101H157N27O29S3Pureza:98%Forma y color:SolidPeso molecular:2309.69Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Forma y color:Odour SolidRTIL 13
CAS:<p>RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).</p>Fórmula:C30H55BrN2O3Forma y color:SolidPeso molecular:571.685Pan-RAS-IN-6
Pan-RAS-IN-6 (compound 24) serves as a DUSP6 inhibitor, effectively reducing MAPK activation in the NCI-H1373-Luc model (DUSP6). It concurrently exhibits notable tumor growth inhibition and regression in the NSCLC brain metastasis mouse model. The compound displays high selectivity and potent inhibitory effects, particularly on KRAS mutation-associated signaling pathways. It demonstrates varied inhibitory activities against distinct KRAS mutants and their interacting proteins. The IC 50 values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively.Fórmula:C46H60N8O5SForma y color:SolidPeso molecular:837.08Ras Inhibitory Peptide acetate
<p>Ras Inhibitory Peptide acetate, involved in cancer-related Ras signaling.</p>Fórmula:C55H95N19O13Pureza:96.63%Forma y color:SolidPeso molecular:1230.46SAH-SOS1A TFA
<p>SAH-SOS1A TFA inhibits SOS1/KRAS interaction, binding wild/mutant KRAS with 106-175 nM affinity and blocks ERK-MAPK signaling, reducing cancer cell viability.</p>Fórmula:C102H160N27F3O30Forma y color:SolidPeso molecular:2301.55KRAS G12D inhibitor 7
CAS:<p>KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.</p>Fórmula:C32H38N8O3Forma y color:SolidPeso molecular:582.709p38 MAP Kinase Inhibitor Ⅵ
CAS:p38 MAP Kinase Inhibitor Ⅵ is a potent p38 MAP Kinase inhibitor with anti-inflammatory activity.Fórmula:C16H13FN2OS2Pureza:98.53%Forma y color:SolidPeso molecular:332.42
